Skip to content
About the CRC
Vision & Goals
Consortium & Structure
Team
Research
Cell-Intrinsic Factors (Area A)
A01: Functions of the dynamic ribosomal epitranscriptome in shaping myeloid plasticity
A02: Mitochondrial RNA modification-driven metabolic plasticity in leukemic stem cells and drug resistance
A03: Targeting metabolic plasticity to overcome chemotherapyresistance in acute myeloid leukemia
A04: Loss of Y chromosome in acute myeloid leukemia drives tumorcell plasticity and drug resistance
A05: Deciphering plasticity of relapse-driving, chemo-resistant LSC states in DNMT3Amut NPM1mut AML
A06: Plastic growth behavior of patients’ AML in vivo: Releasing dormant cells from their protective niche
A07: Myeloid antigen plasticity as critical determinant of AML immune surveillance
Cell-Extrinsic Factors (Area B)
B01: Predicting response to venetoclax/azacitidine in AML by determining cytologic variability in AML blasts with generative AI image analysis combined with single-celltranscriptomics
B02: Investigation into the plastic state of dormancy in JAK2-V617F driven myeloproliferative neoplasms (MPNs) and secondary acute myeloid leukemias (sAMLs)
B03: Multi-modal proteomics to understand and overcome nicherelatedadaptive drug-resistance mechanisms in FLT3-mutated AML
B04: Dissecting mechanisms of immunotherapy-induced plasticity in AML through multi-omics and genome-wide CRISPR screens
B05: Characterizing lineage plasticity of KMT2A/AFF1-rearranged acute leukemia under therapeutic pressure from CAR T cells
B06: Leukemia cell plasticity and NK cell activity as determinants of relapse in AML
B07: Single cell multi-omics to unravel niche plasticity in AML therapy resistance
B08: Spatial and epigenetic plasticity during leukemia development
B09: Inflammation-driven plasticity in disease progression in Advanced Systemic Mastocytosis
B10: Cellular plasticity driven by innate immune activation in DDX41-mediated myeloid malignancies
B11: Deciphering and therapeutically exploiting immunerelated cellular plasticity during allogeneic stem celltransplantation in myeloid malignancies
Core Projects
INF: Data management, information infrastructure and Application
Z01: Central administration
Z02: Clinically annotated primary tumor cells and mouse clinics for patient-derived xenograft (PDX) models
Z03: Proteomic and single-cell transcriptomic landscapes of cellular plasticity in myeloid malignancies
Publications
Events
Events Archive
News
Contact
About the CRC
Vision & Goals
Consortium & Structure
Team
Research
Cell-Intrinsic Factors (Area A)
A01: Functions of the dynamic ribosomal epitranscriptome in shaping myeloid plasticity
A02: Mitochondrial RNA modification-driven metabolic plasticity in leukemic stem cells and drug resistance
A03: Targeting metabolic plasticity to overcome chemotherapyresistance in acute myeloid leukemia
A04: Loss of Y chromosome in acute myeloid leukemia drives tumorcell plasticity and drug resistance
A05: Deciphering plasticity of relapse-driving, chemo-resistant LSC states in DNMT3Amut NPM1mut AML
A06: Plastic growth behavior of patients’ AML in vivo: Releasing dormant cells from their protective niche
A07: Myeloid antigen plasticity as critical determinant of AML immune surveillance
Cell-Extrinsic Factors (Area B)
B01: Predicting response to venetoclax/azacitidine in AML by determining cytologic variability in AML blasts with generative AI image analysis combined with single-celltranscriptomics
B02: Investigation into the plastic state of dormancy in JAK2-V617F driven myeloproliferative neoplasms (MPNs) and secondary acute myeloid leukemias (sAMLs)
B03: Multi-modal proteomics to understand and overcome nicherelatedadaptive drug-resistance mechanisms in FLT3-mutated AML
B04: Dissecting mechanisms of immunotherapy-induced plasticity in AML through multi-omics and genome-wide CRISPR screens
B05: Characterizing lineage plasticity of KMT2A/AFF1-rearranged acute leukemia under therapeutic pressure from CAR T cells
B06: Leukemia cell plasticity and NK cell activity as determinants of relapse in AML
B07: Single cell multi-omics to unravel niche plasticity in AML therapy resistance
B08: Spatial and epigenetic plasticity during leukemia development
B09: Inflammation-driven plasticity in disease progression in Advanced Systemic Mastocytosis
B10: Cellular plasticity driven by innate immune activation in DDX41-mediated myeloid malignancies
B11: Deciphering and therapeutically exploiting immunerelated cellular plasticity during allogeneic stem celltransplantation in myeloid malignancies
Core Projects
INF: Data management, information infrastructure and Application
Z01: Central administration
Z02: Clinically annotated primary tumor cells and mouse clinics for patient-derived xenograft (PDX) models
Z03: Proteomic and single-cell transcriptomic landscapes of cellular plasticity in myeloid malignancies
Publications
Events
Events Archive
News
Contact
Menu
Dr. Dr. Franziska Blaeschke
Principal Investigator
KiTZ, Hopp Children´s Cancer Center Heidelberg
Research
Contact
WordPress Cookie Notice by Real Cookie Banner
